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Objective To describe maternal haemodynamic differences in
gestational hypertension with small-for-gestational-age babies
(HDP + SGA), gestational hypertension with appropriate-for-
gestational-age babies (HDP-only) and control pregnancies.
Design Prospective cohort study.
Setting Tertiary Hospital, UK.
Population Women with gestational hypertension and healthy
pregnant women.
Methods Maternal haemodynamic indices were measured using a
non-invasive Ultrasound Cardiac Output Monitor (USCOM-1A)
and corrected for gestational age and maternal characteristics
using device-specific reference ranges.
Main outcome measures Maternal cardiac output, stroke volume,
systemic vascular resistance.
Results We included 114 HDP + SGA, 202 HDP-only and 401
control pregnancies at 26–41 weeks of gestation. There was no
significant difference in the mean arterial blood pressure (110
versus 107 mmHg, P = 0.445) between the two HDP groups at
presentation. Pregnancies complicated by HDP + SGA had
significantly lower median heart rate (76 versus 85 bpm versus
83 bpm), lower cardiac output (0.85 versus 0.98 versus
0.97 MoM) and higher systemic vascular resistance (1.4 versus 1.0
versus 1.2 MoM) compared with control and HDP-only
pregnancies, respectively (all P < 0.05).
Conclusion Women with HDP + SGA present with more severe
haemodynamic dysfunction than HDP-only. Even HDP-only
pregnancies exhibit impaired haemodynamic indices compared with
normal pregnancies, supporting a role of the maternal cardiovascular
system in gestational hypertension irrespective of fetal size. Central
haemodynamic changes may play a role in the pathogenesis of pre-
eclampsia and should be considered alongside placental aetiology.
Keywords Cardiac output, heart rate, hypertension, maternal
haemodynamics, non-invasive monitoring, pre-eclampsia, small
for gestational age, systemic vascular resistance.
Tweetable abstract Hypertensive disorders of pregnancy are
associated with worse maternal haemodynamic function when
associated with small-for-gestational-age birth.
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Introduction
There is increasing evidence for the role of the maternal
cardiovascular system in the development of gestational
hypertension and pre-eclampsia. Not only do hypertensive
disorders of pregnancy (HDP) share the same risk factors
as cardiovascular disease,1–5 but there is also good echocar-
diographic evidence of structural and functional changes in
pregnancies affected by pre-eclampsia. For example, in
pregnancies complicated by pre-eclampsia at term, global
diastolic dysfunction has been observed in 40% of them
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compared with 14% of control pregnancies, while in pre-
term pre-eclampsia biventricular systolic dysfunction was
seen in 26% and severe left ventricular hypertrophy was
seen in 19% compared with 0% of control women.6–8 Fur-
thermore, women who develop pre-eclampsia and gesta-
tional hypertension are at an increased risk of developing
postpartum hypertension and cardiovascular disease in later
life, with the risk correlating to the severity of their hyper-
tension disorder of pregnancy.9–16
Different classifications of hypertension in pregnancy
have been proposed, which are differentiated by the devel-
opment of proteinuria, maternal organ dysfunction or fetal
growth restriction in pre-eclampsia,17 as well as different
variations on ‘early’ and ‘late-onset’ pre-eclampsia. These
two conditions have typically been separated at 34 weeks of
gestation and have been purported as different disease enti-
ties with different pathological mechanisms.18–20 Early-on-
set pre-eclampsia is a placenta-mediated disease secondary
to a failure of the physiological transformation of the spiral
arteries into dilated, non-elastic vessels to allow for maxi-
mal maternal–placental blood flow. The resulting narrow
vessels impede blood flow leading to placental ischaemia,
which results in small-for-gestational-age fetuses in addi-
tion to hypertension.20–25 Late-onset disease is thought to
be secondary to maternal cardio-metabolic dysfunction,
which is less likely to be associated with small-for-gesta-
tional-age babies.18–20 An alternative explanation to the
theory of two separate disease mechanisms, is that gesta-
tional hypertension and pre-eclampsia are a disease contin-
uum, with its severity related to the degree of underlying
maternal haemodynamic dysfunction; notably a lack of
increase in maternal cardiac output and decrease in sys-
temic vascular resistance as would be expected in normal
pregnancy.26
The objective of this study was to describe maternal
haemodynamic differences (stroke volume, heart rate, car-
diac output and systemic vascular resistance), using a non-
invasive continuous-wave Doppler device,27,28 in hyperten-
sive disorders with and without small-for-gestational-age
babies and in control pregnancies. We hypothesised that
impaired maternal haemodynamic function would predis-
pose to small-for-gestational-age birth.
Materials and methods
Study population and recruitment
This was a prospective study of pregnancies complicated by
hypertensive disorders and control normotensive pregnan-
cies seen at a tertiary referral centre between January 2012
and May 2018. The inclusion criteria were singleton preg-
nancies with a viable fetus at 26 weeks of gestation or
greater with gestational hypertension, defined according to
the International Society for the Study of Hypertension in
Pregnancy (ISSHP) 2014 revised criteria,17 or uncompli-
cated singleton pregnancies. The exclusion criteria were
women with multiple pregnancies, a history of chronic
hypertension or cardiac disease and pregnancies compli-
cated by aneuploidy, genetic syndromes or major structural
fetal abnormalities. A small-for-gestational-age neonate was
defined as having a birthweight below the 10th centile.
Fetal growth restriction was defined as per the Delphi Con-
sensus agreement.29 At <32 weeks of gestation: abdominal
circumference/estimated fetal weight <3rd centile or absent
end-diastolic flow in the umbilical artery or abdominal cir-
cumference/estimated fetal weight <10th centile combined
with uterine artery pulsatility index >95th centile and/or
umbilical artery pulsatility index >95th centile. At
≥32 weeks of gestation: abdominal circumference/estimated
fetal weight <3rd centile or at least two out of the follow-
ing: (i) abdominal circumference/estimated fetal weight
<10th centile, (ii) abdominal circumference/estimated fetal
weight crossing >two quartiles, (iii) cerebral placental ratio
<5th centile or umbilical artery pulsatility index >95th cen-
tile. A centile calculation obtained from a study of 92 000
healthy neonates from a similar population to ours was
used. This calculator was chosen over the Intergrowth-21st
standard as it has been shown to detect a greater propor-
tion of small-for-gestational-age fetuses in our popula-
tion.30 Women with hypertensive disorders of pregnancy
were divided into two groups: those that had a small-for-
gestational-age neonate (HDP + SGA) and those with an
appropriately grown neonate (HDP-only). According to the
modified ISSHP criteria, those in the HDP + SGA group
had pre-eclampsia whereas those in the HDP-only group
had either gestational hypertension or pre-eclampsia. All
women with hypertensive disorders of pregnancy were
managed as per the hospital protocol, which is based on
the National Institute for Health and Care Excellence
(NICE) guidance.31 At less than 34 weeks of gestation,
delivery was indicated after a course of steroids if the
mother developed severe refractory hypertension or if there
was evidence of severe maternal or fetal compromise (sys-
tolic blood pressure ≥160 mmHg or diastolic blood pres-
sure ≥110 mmHg not controlled by first- and second-line
treatment; pulmonary oedema or cyanosis, platelet count
≤100 x 109/L, transaminases more than twice the normal
limit, evidence of cerebral disturbance, oliguria, fetal
growth restriction with Doppler scans indicating delivery
or abnormal computerised cardiotocography. Between 34+0
and 36+6 weeks of gestation, delivery was indicated after a
course of steroids if the mother developed pre-eclampsia
and there was evidence of maternal or fetal compromise.
After 37 weeks of gestation, delivery was usually indicated
within 24–48 hours if the mother developed pre-eclampsia.
For women with gestational hypertension, delivery was
planned on an individual basis by a senior clinician. The
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control group had no pre-existing cardiac or metabolic dis-
ease. Those control pregnancies that subsequently devel-
oped hypertension or resulted in the birth of a small-for-
gestational-age neonate were excluded from the analysis.
Women in the control group were recruited whie attending
an antenatal visit or a third-trimester ultrasound assess-
ment (placental localisation, presentation, measuring small
or large for dates). Written consent was obtained from all
study participants and research ethics committee approval
(12/LO/0810) was obtained before performing the study
investigations. There was no specific funding for this study;
however, HP was supported by a grant from the National
Institute for Health Research Collaboration for Leadership
in Applied Health Research and Care South London at
King’s College Hospital NHS Foundation Trust.
Research investigations
Haemodynamic assessment was performed at diagnosis of
gestational hypertension and, where possible, before the
commencement of any antihypertensive medication. The
proportion of women on medication at the time of treat-
ment and the kind of treatment was recorded. All haemo-
dynamic assessments were performed in the same room,
under standardised conditions for the entire cohort. Mater-
nal height (m), weight (kg) and brachial blood pressure
(mmHg) were obtained before haemodynamic assessment.
Blood pressure was obtained using an upper arm automatic
blood pressure monitor (Microlife; Microlife AG Swiss
Corporation, Widnau, Switzerland), in a semi-recumbent
position and using an appropriately sized cuff. Mean arte-
rial pressure was calculated as (29 diastolic blood pres-
sure + systolic blood pressure)/3. Haemodynamic
assessment was performed using the USCOM-1A device
(see Supplementary material, Figure S1) with the woman
in a semi-recumbent position. The probe was placed at the
suprasternal notch and moved in three dimensions to
obtain an optimal waveform, representing the velocity of
blood at the left ventricular outflow tract. The Doppler
profile was displayed on the device’s computer screen in
real-time and once a satisfactory profile was obtained, the
recording was stopped, and the quality of the recording
was reviewed. Each Doppler profile represents the velocity
time integral, which equates to the distance travelled by a
column of blood during each cardiac cycle. The Doppler
acquisitions used for analysis had a minimum of two con-
secutive Doppler profiles (cardiac cycles). Acquisitions with
the least amount of interference and the best quality veloc-
ity time integrals, deemed by the study investigators to best
represent transaortic blood flow, were used for measure-
ments. USCOM 1A uses an in-built anthropometric algo-
rithm to calculate the diameter of the aortic root based on
the woman’s height. By multiplying the velocity of blood
being ejected by the known cross-sectional area of the
aortic valve, the volume of blood being ejected can be cal-
culated, giving the stroke volume. By calculating the inter-
val between successive ejections of blood, the heart rate can
be calculated, and by multiplying the stroke volume by the
heart rate, the cardiac output can be obtained. By entering
the woman’s mean arterial pressure, the device will also
calculate systemic vascular resistance (systemic vascular
resistance = mean arterial pressure/cardiac output). We
chose to measure cardiac output and systemic vascular
resistance because of their direct influence on blood pres-
sure. All measurements were performed by trained investi-
gators. Repeatability and reproducibility studies of USCOM
1A have shown excellent agreement between trained oper-
ators, including in pregnant women.32–34 Cardiac output,
stroke volume and systemic vascular resistance were con-
verted into multiples of the median (MoM) to adjust for
gestational age as well as maternal height, maternal weight
and maternal age. These characteristics have been shown to
influence maternal haemodynamic indices in a cohort of
600 pregnancies used to derive device-specific reference
ranges using the USCOM 1A device.35
Statistical analysis
A sample size calculation was performed based on a study
of preterm pre-eclampsia pregnancies and control pregnan-
cies using echocardiography that found a cardiac index dif-
ference of 0.6 l/min/m2 (Pre-eclampsia group 2.6 l/min/m2
[2.1–3.1], Control group 3.2 l/min/m2 [2.7–3.7]).7 Standard
deviation was calculated from the confidence intervals and
a formula for difference in means was used to obtain sam-
ple size. We calculated that 94 participants would be
required in the larger group to detect a difference between
the groups at 90% power with a type 1 error of 0.05, based
on a 2:1 ratio. Data distribution was assessed using the
Shapiro–Wilk test as well as graphical methods. Categorical
data were presented as number and percentage, while con-
tinuous data were presented as the median and interquar-
tile range. Statistical analysis was performed using the chi-
square test, Mann–Whitney U-test or Student’s t-test.
Spearman’s rank correlation was used to explore the rela-
tionship between haemodynamic indices and birthweight.
Sub-group analysis was performed according to whether
the hypertensive women were receiving antihypertensive
therapy or not in order to explore any potential confound-
ing effect on the haemodynamic variables. A direct com-
parison between treated and untreated women was also
performed. A P value < 0.05 was considered statistically
significant. Statistical software (SPSS 25.0; SPSS Inc., Chi-
cago, IL, USA) was used to conduct the analysis.
Patient involvement and core outcome sets
Participants were not involved in the design or undertaking
of this study. At the time of study inception, no core
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outcome set was available for pre-eclampsia and this study
does not evaluate a treatment or intervention.
Results
We recruited 322 women with hypertensive disorders of
pregnancy and 452 control women to the study. Six of the
hypertensive cases were excluded because of loss to follow
up and 51 of the control women were excluded because of
an adverse pregnancy outcome. The flow of participants is
shown in the Supplementary material (Figure S2). The
maternal demographic and pregnancy details are shown in
Table 1. Women in both HDP groups were heavier and
shorter than control women and also delivered smaller
babies at an earlier gestation. There were significantly more
women of Afro-Caribbean and Asian ethnicity in the
HDP + SGA group compared with the HDP-only and con-
trol groups. There was no significant difference in the pro-
portion of women taking antihypertensive medication in
the HDP + SGA and HDP-only groups at the time of
assessment (83/114 [31%] versus 163/202 [39%],
P = 0.105). There was no difference in the haematocrit
level between the HDP + SGA group and the HDP-only
group (0.38 l/l [0.34–0.39] versus 0.36 l/l [0.35–0.38],
P = 0.632).
The haemodynamic differences between the two HDP
groups and the control group are shown in Table 2 and
Figure 1. Both HDP groups had a higher mean arterial
pressure at the start of pregnancy and at recruitment com-
pared with the control group. Women with HDP + SGA
had significantly (all P < 0.001) lower median heart rate
(76 versus 85 bpm), lower cardiac output (0.85 versus
0.98 MoM) and higher systemic vascular resistance (1.4
versus 1.0 MoM) and uterine artery pulsatility index (1.7
versus 1.0 MoM) than control women. Women with
HDP + SGA also had significantly (all P < 0.01) lower
heart rate (76 versus 83 bpm) and cardiac output (0.85
versus 0.97 MoM), and higher systemic vascular resistance
(1.4 versus 1.2 MoM) and uterine artery pulsatility index
(1.7 versus 1.1 MoM) compared with women with HDP-
only. Women with HDP-only had significantly lower med-
ian heart rate (83 versus 85 bpm, P = 0.028) and higher
systemic vascular resistance (1.2 versus 1.0 MoM,
P < 0.001) and uterine artery pulsatility index (1.1 versus
1.0 MoM, P < 0.001) than control women. There was no
significant difference in mean arterial pressure (110 versus
107 mmHg, P = 0.445) or stroke volume (1.0 versus
0.99 MoM, P = 0.411) between the two HDP groups at
presentation. Birthweight centile was positively correlated
with cardiac output MoM (Rs = 0.287, P < 0.001) and
heart rate (Rs = 0.256, P < 0.001) and negatively correlated
with systemic vascular resistance MoM (Rs = 0.313,
P < 0.001).
Differences in maternal haemodynamic indices between
the HDP + SGA and HDP-only groups persisted, even after
excluding women taking antihypertensive treatment
(Table 3). Women with HDP + SGA had significantly (all
P < 0.001) lower median heart rate (77 versus 85 bpm),
lower cardiac output (0.84 versus 0.98 MoM), and higher
systemic vascular resistance (1.4 versus 1.0 MoM) and uter-
ine artery pulsatility index (1.7 versus 1.0 MoM) than con-
trol women. Women with HDP + SGA also had
significantly (all P < 0.05) lower heart rate (77 versus
83 bpm) and cardiac output (0.84 versus 0.99 MoM), and
higher systemic vascular resistance (1.4 versus 1.2 MoM)
and uterine artery pulsatility index (1.7 versus 1.1 MoM)
compared with women with HDP-only. When comparing
women who were taking antihypertensive medication with
those who were not, there were no significant differences in
the maternal haemodynamic indices in the HDP + SGA
group. In the HDP-only group, women who were on anti-
hypertensive medication had significantly lower cardiac
output MoM (0.90 [0.77–1.0] versus 0.99 [0.87–1.1],
P = 0.026) and significantly higher systemic vascular resis-
tance MoM (1.3 [1.1–1.6] versus 1.2 [1.1–1.4], P = 0.036)
compared with women not on antihypertensive therapy
(see Supplementary material, Table S1). On further analysis
of the HDP + SGA group, there were no significant differ-
ences in the maternal haemodynamics of those women
with fetuses with fetal growth restriction compared with
those with small-for-gestational-age alone (see Supplemen-
tary material, Table S2).
Discussion
Main findings
Our study demonstrates that women with HDP + SGA
present with lower cardiac output and higher systemic vas-
cular resistance than women with HDP-only. Even HDP-
only women exhibit lower heart rate and higher systemic
vascular resistance compared with women with normal
pregnancies. Stroke volume and mean arterial blood pres-
sure were not significantly different between the two HDP
groups, indicating that maternal heart rate is the main
determinant of lower cardiac output and higher systemic
vascular resistance in HDP + SGA.
Strengths and limitations
The main strengths of our study are the prospective assess-
ment of a large cohort of pregnancies with pre-eclampsia
or gestational hypertension as well as control pregnancies.
Furthermore, for the haemodynamic variables that could
be affected by gestational age and maternal factors, we cor-
rected using device-specific reference ranges. One limitation
of our study is that it is cross-sectional in nature, and
although we can observe the trend of measurements across
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Table 1. Demographic and pregnancy characteristics of pregnant women with hypertension and small-for-gestational-age, hypertension-only and
normotensive control pregnancies. Data presented as median (interquartile range) or number (%)
Group P value
HDP + SGA
(n = 114)
HDP-only
(n = 202)
Controls
(n = 401)
HDP + SGA vs
control
HDP-only vs
control
HDP + SGA vs
HDP-only
Maternal age (years) 31 (28–35) 33 (29–36) 32 (28–36) 0.185 0.473 0.085
Gestation at assessment
(weeks)
34.0 (29.8–36.0) 36.4 (34.4–38.1) 36.0 (31.4–36.4) <0.001 <0.001 <0.001
Maternal weight (kg) 78.8 (69.2–92.9) 88.2 (78.4–99.9) 75.7 (68.1–85.0) 0.016 <0.001 <0.001
Maternal height (cm) 160 (157–166) 165 (160–170) 165 (160–169) <0.001 0.363 <0.001
Body mass index (kg/m2) 30.5 (27.2–35.1) 32.0 (28.9–35.8) 28.1 (25.3–31.2) <0.001 <0.001 0.054
Body surface area (m2) 1.9 (1.8–2.0) 2.0 (1.9–2.2) 1.9 (1.8–2.0) 0.193 <0.001 <0.001
Smoking in pregnancy 4 (3.5) 4 (2.0) 22 (5.5) 0.395 0.045 0.406
Nulliparous 75 (65.8) 108 (53.5) 207 (51.6) 0.007 0.669 0.033
Ethnicity
Caucasian 48 (42.1) 140 (69.3) 260 (64.8) <0.001
Afro-Caribbean 26 (22.8) 25 (12.4) 48 (12.0) <0.010
Asian 35 (30.7) 28 (13.9) 69 (17.2) <0.001
Mixed/other 5 (4.4) 9 (4.5) 24 (6.0) 0.653
Antihypertensive treatment
at assessment
31 (27.2) 39 (19.3) 0 (0.0) – – 0.105
Haematocrit (l/l) 0.38 (0.34–0.39) 0.36 (0.35–0.38) – – – 0.632
Birthweight centile 3 (1–6) 43 (23–74) 50 (25–74) <0.001 0.353 <0.001
Gestation at delivery (weeks) 36.1 (32.8–38.0) 39.0 (37.6–39.9) 40.0 (39.0–40.9) <0.001 <0.001 <0.001
The bold values represented statistically significant P-values.
Table 2. Haemodynamic indices of pregnant women with hypertension and small-for-gestational-age, hypertension-only and normotensive
control pregnancies. Data presented as median (interquartile range)
Group P value
HDP + SGA
(n = 114)
HDP-only
(n = 202)
Controls
(n = 401)
HDP + SGA vs
Control
HDP-only vs
Control
HDP + SGA
vs
HDP-only
Booking mean arterial
pressure (mmHg)
87 (83–96) 92 (87–98) 82 (76–88) <0.001 <0.001 0.001
Examination mean arterial
pressure (mmHg)
110 (101–115) 107 (101–113) 87 (81–92) <0.001 <0.001 0.445
Heart rate (bpm) 76 (70–85) 83 (72–91) 85 (76–95) <0.001 0.022 0.002
Cardiac output (l/min) 5.7 (4.9–6.8) 6.5 (5.6–7.5) 6.6 (5.8–7.5) <0.001 0.374 <0.001
Stroke volume (ml) 76.9 (61.0–88.6) 78.7 (66.2–92.5) 78.7 (67.4–89.2) 0.147 0.475 0.075
Systemic vascular resistance
(dynes-sec-cm5)
1519 (1288–1741) 1329 (1123–1550) 1061 (918–1210) <0.001 0.001 <0.001
Cardiac output MoM 0.85 (0.76–1.0) 0.97 (0.83–1.1) 0.98 (0.87–1.1) <0.001 0.206 <0.001
Stroke volume MoM 1.0 (0.85–1.1) 0.99 (0.87–1.2) 0.98 (0.87–1.1) 0.984 0.250 0.411
Systemic vascular resistance
MoM
1.4 (1.2–1.6) 1.2 (1.1–1.5) 1.0 (0.89–1.2) <0.001 <0.001 <0.001
Uterine artery mean pulsatility
index MoM
1.7 (1.2–2.1) 1.1 (0.91–1.4) 1.0 (0.82–1.1) <0.001 <0.001 <0.001
The bold values represented statistically significant P-values.
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different gestational ages, we cannot report true longitudi-
nal changes for each variable. Second, a minority of women
in this study were taking antihypertensive medication at
the time of assessment. However, there was no difference
in the proportion of women between the two groups and
sub-group analysis revealed that the reported findings per-
sisted when women taking antihypertensive medication
were excluded. Finally, we cannot exclude the possibility of
residual confounding affecting the study findings, but the
inclusion of a relatively large number of women and well-
defined groups partially mitigate the magnitude of such
effects.
Interpretation (in light of other evidence)
Previous studies of haemodynamic changes in pre-eclampsia
have yielded conflicting results, with some authors describing
pre-eclampsia as a high-output hyperdynamic state,36–38
whereas others have described lower cardiac output with
higher systemic vascular resistance.7,39–41 These contrasting
findings may be the result of the heterogeneity of the popula-
tion studied (with and without small-for-gestational-age
infants) as well as the stage of the clinical disease at which
the measurements were taken. This study shows that pre-
eclampsia exhibits differences in haemodynamic profile
depending on whether it is associated with a small fetus.
Rang et al.42 undertook a longitudinal study of maternal
haemodynamic indices and described lower cardiac output
and higher systemic vascular resistance from preconception
up to 32 weeks of gestation in women with HDP + SGA
compared with women with HDP-only. Our study confirms
the latter findings and additionally shows that they persist
until term. Ferrazzi et al.43 compared the same HDP groups
Figure 1. Differences in (a) cardiac output multiple of the median (MoM), (b) heart rate (bpm) and (c) systemic vascular resistance MoM between
the Hypertension with small-for-gestational-age and Hypertension-only groups.
Table 3. Haemodynamic indices of pregnant women with hypertension and small-for-gestational-age, hypertension-only and normotensive
control pregnancies with women on antihypertensive medication excluded. Data presented as median (interquartile range)
Group P value
HDP + SGA
(n = 83)
HDP-only
(n = 163)
Controls
(n = 401)
HDP + SGA vs
Control
HDP-only vs
Control
HDP + SGA
vs
HDP-only
Booking mean arterial
pressure (mmHg)
87 (81–95) 91 (87–98) 82 (76–88) <0.001 <0.001 <0.001
Examinaton mean arterial
pressure (mmHg)
109 (100–113) 107 (102–113) 87 (81–92) <0.001 <0.001 0.820
Heart rate (bpm) 77 (70–87) 83 (71–94) 85 (76–95) <0.001 0.046 0.011
Cardiac output (l/min) 5.7 (5.0–6.6) 6.5 (5.7–7.6) 6.6 (5.8–7.5) <0.001 0.589 0.003
Stroke volume (ml) 76.9 (63.4–88.0) 79.0 (65.8–92.5) 78.7 (67.4–89.2) 0.189 0.303 0.076
Systemic vascular resistance
(dynes-sec-cm5)
1512 (1276–1741) 1325 (1098–1528) 1061 (918–1210) <0.001 <0.001 <0.001
Cardiac output MoM 0.84 (0.77–0.98) 0.99 (0.87–1.1) 0.98 (0.87–1.1) <0.001 0.636 <0.001
Stroke volume MoM 0.97 (0.84–1.1) 1.0 (0.87–1.2) 0.98 (0.87–1.1) 0.711 0.084 0.150
Systemic vascular resistance
MoM
1.4 (1.2–1.6) 1.2 (1.1–1.4) 1.0 (0.89–1.2) <0.001 <0.001 <0.001
Uterine artery mean pulsatility
index MoM
1.7 (1.2–2.1) 1.1 (0.91–1.3) 1.0 (0.82–1.1) <0.001 0.001 <0.001
The bold values represented statistically significant P-values.
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(with and without small-for-gestation-age fetuses) and
reported lower cardiac output and higher systemic vascular
resistance in HDP + SGA. However, they found no signifi-
cant difference in heart rate or stroke volume, presumably
because their study was limited by smaller numbers and by
not correcting haemodynamic indices for gestational age or
maternal factors. Tay et al. reported similar findings of a
lower cardiac output and higher systemic vascular resistance
in women with pre-eclampsia with fetal growth restriction,
but higher cardiac output and lower systemic vascular resis-
tance in women with pre-eclampsia alone compared with
control women. This contrasting difference may be a result
of the use of haemodynamic devices unvalidated in preg-
nancy, lack of device-specific pregnancy reference ranges and
because their HDP-only group comprised just 13 women,
four of whom were taking antihypertensive medication.38,44
The vast majority of haemodynamic studies have reported
higher systemic vascular resistance in HDP consistent with a
diagnosis of hypertension.
Our findings, along with those described by the studies
above, support the theory that gestational hypertension and
pre-eclampsia are a disease-continuum, with those women
with a more severe clinical picture (HDP + SGA) having the
lowest cardiac output and highest systemic vascular resis-
tance. Those with less severe disease (HDP-only) have less
impaired maternal haemodynamic function, but still demon-
strate lower heart rate and systemic vascular resistance com-
pared with control women. This pattern of relative maternal
cardiac dysfunction occurs regardless of gestational age at
onset, making it less conceivable that there are two different
causes of pre-eclampsia. As in previous studies, we found
that uterine artery pulsatility index is positively correlated
with systemic vascular resistance and negatively correlated
with cardiac output.45,46 This measure of impendence at the
uteroplacental interface has always been considered to reflect
the failure of the physiological transformation of the spiral
arteries47,48 but it is perhaps more appropriate to consider
the uteroplacental circulation and central maternal haemo-
dynamics together. Spaanderman et al.49 found higher pre-
pregnancy uterine artery pulsatility index in normotensive
women with a history of pre-eclampsia who developed
small-for-gestational-age fetuses in the subsequent preg-
nancy. This suggests that uterine and perhaps systemic impe-
dance can be raised before the development of the placenta
and may be a reflection of the underlying maternal cardio-
vascular health itself. Preconception studies of haemodynam-
ics have also demonstrated lower cardiac output and higher
systemic vascular resistance in pregnancies subsequently
complicated by pre-eclampsia.42,50
Clinical and research implications
One limitation of the placental-cause theory of pre-eclamp-
sia is that vascular and villous abnormalities are not seen
in the majority of pre-eclampsia or gestational hypertension
cases.21,22,25,51,52 We have shown a spectrum of haemody-
namic dysfunction across more severe to less severe pre-
eclampsia and our results support the need for further
work into understanding maternal haemodynamic changes
in pregnancy as well as the interaction between placental
and central haemodynamics. Maintenance of normal blood
pressure is dependent on the balance between cardiac out-
put and systemic vascular resistance.53 In pre-eclampsia
and gestational hypertension, systemic vascular resistance is
increased with a relative deficiency in cardiac output, which
appears, from our findings, to be due to a lower heart rate,
rather than stroke volume. These changes may be caused
by increased uteroplacental resistance contributing to sys-
temic vascular resistance and afterload. A lack of sympa-
thetic response may contribute by failed elevation in heart
rate and/or contractility to overcome afterload. Alterna-
tively, if there is a pre-existing lower cardiac output and
higher systemic vascular resistance, the maternal circulation
will be working maximally to maintain uteroplacental per-
fusion. Where this is not sufficient, our study suggests that
this will predispose to SGA and perhaps fetal growth
restriction.
In normal pregnancy, heart rate should increase through-
out gestation but in pre-eclampsia and gestational hyperten-
sion this does not happen to the same extent. Alternatively, it
may be that the heart rate is decreased in pre-eclampsia and
gestational hypertension in order to increase ventricular fill-
ing time, and subsequently maintain stroke volume. Monitor-
ing changes in cardiac output and systemic vascular resistance
after the initiation of antihypertensive therapy could help to
optimise blood pressure control without impacting on utero-
placental perfusion and placental function.
Conclusion
The clinical severity of gestational hypertension and pre-
eclampsia is reflected in underlying maternal haemody-
namic function, with lower heart rate, cardiac output and
higher systemic vascular resistance in more severe
HDP + SGA. Central haemodynamic changes may play an
important role in the pathogenesis of pre-eclampsia irre-
spective of the finding of fetal growth restriction.
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